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Background: Up-regulation of HO-1 by genetic manipulation or pharmacological pre-treatment has been reported
to provide benefits in several animal models of myocardial infarction (MI). However, its efficacy following MI
initiation (as in clinical reality) remains to be tested. Therefore, this study investigated whether HO-1
over-expression, by cobalt protoporphyrin (CoPP) administered after LAD ligation, is still able to improve
functional and structural changes in left ventricle (LV) in a rat model of 4-week MI.
Methods: A total of 144 adult male Wistar rats were subjected to either left anterior coronary artery ligation or
sham-operation. The effect of CoPP treatment (5 mg/kg i.p. at the end of the surgical session and, then, once a
week for 4 weeks) was evaluated on the basis of survival, electro- and echocardiography, plasma levels of B-type
natriuretic peptide (BNP), endothelin-1 and prostaglandin E2, coronary microvascular reactivity, MI size, LV wall
thickness and vascularity. Besides, the expression of HO-1 and connexin-43 in different LV territories was assessed
by western blot analysis and immunohistochemistry, respectively.
Results: CoPP induced an increased expression of HO-1 protein with >16 h delay. CoPP treatment significantly
reduced mortality, MI size, BNP concentration, ECG alterations, LV dysfunction, microvascular constriction, capillary
rarefaction and restored connexin-43 expression as compared to untreated MI. These functional and structural
changes were paralleled by increased HO-1 expression in all LV territories. HO activity inhibition by
tin-mesoporphyrin abolished the differences between CoPP-treated and untreated MI animals.
Conclusions: This is the first report demonstrating the putative role of pharmacological induction of HO-1 following
coronary occlusion to benefit infarcted and remote territories, leading to better cardiac function in a 4-week MI
outcome.
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Myocardial infarction (MI) is a life-threatening dynamic
process initiating with coronary occlusion and frequently
progressing towards chronic heart failure in survivors. In
recent years much research has been devoted to revascu-
larization of ischemic territory by both pharmacological
and mechanical interventions in the very acute phase, in
order to minimize ischemic necrosis and infarct size and
reduce early mortality. However, beyond the initial phase,
the final outcome of MI is conditioned by a long series of
biological processes, which on one hand modulates loss
and regeneration of myocardial tissue in the infarcted ter-
ritory, and on the other remodels the remote, viable myo-
cardium with a relevant progressive loss of function and
failure. Noticeably, the unfavorable outcome of MI is
primarily related to the activation of the neuro-humoral
system but only partially to infarct size. The well-
documented beneficial effects of long-term treatment with
beta-blockers, diuretics, ace-inhibitors and angiotensin re-
ceptor blockers support this view [1-3]. Moreover, among
biological factors intervening in structural and functional
modifications that characterize the infarcted heart, inflam-
mation and oxidation play a prominent role during the en-
tire time course of MI, from early necrosis to heart failure
[4-7]. In this study we have focused on the potential use of
pharmacological intervention too late to save irreversibly
injured ischemic myocardium, but timed to limit add-
itional myocardial loss due to inflammatory, oxidative and
apoptotic processes [8,9], accelerate the repair process and
reduce ventricular remodeling.
The heme oxygenase-1 (HO-1) gene has cytoprotective
properties mediated by its anti-oxidative, anti-inflammatory
and anti-apoptotic effects. In animal models of MI, HO-1
over-expression in either transgenic [10-12] or transfected
rodents [13-15] or even pre-treatment with cobalt proto-
porphyrin IX (CoPP) [16], a powerful and widely used
inducer of HO-1 expression [17,18], reduced infarct size
as well as ventricular remodeling, enhanced endothelial
function, promoted neoangiogenesis and restored cardiac
metabolism. Thus, it is well established that HO-1 over-
expression, when present at the time of coronary occlusion,
is able to minimize myocardial damage and improve out-
come through a series of cytoprotective activities and rep-
arative processes involving formation of new vascular
structures and myocytes [16]. Unfortunately, the above ex-
perimental conditions are far from the clinical reality,
which allows treatment only after infarct initiation. To the
best of our knowledge the only documentation of the bene-
ficial effect of post-MI HO-1 over-expression comes from
Lin and coworkers [19] who showed that invasive injection
of recombinant AAV bearing HO-1 gene into the border-
zone early after induction of MI in mice, promoted neovas-
cularization in the ischemic region and significantly limited
left ventricular (LV) fibrosis and dysfunction at 4 weeks.Thus, in view of a potential novel pharmacological chal-
lenge, the aim of our study was to assess whether adminis-
tration of a pharmacological HO-1 activation, when
chances to save ischemic myocardium are greatly reduced
or even nil, has any effect on MI outcome. This is a ‘proof
of concept’ experimental controlled trial (treated vs un-
treated vs sham MI). We hypothesized that when ischemic
damage was already irreversible, HO-1 over-expression
would be able, by its well-documented anti-oxidant, anti-
inflammatory, anti-apoptotic and angiogenetic effects, to
positively modulate those post-ischemic phenomena that
(beyond the initial ischemic damage) significantly contrib-
ute to final infarct size, left ventricular dilation and remod-
eling, and progression towards heart failure. In order to
induce HO-1 over-expression we administered CoPP at
the end of the surgical procedure of LAD ligation in the
rat, following the preliminary documentation that CoPP




Animals used in this investigation conformed to the re-
commendations in the Guide for the Care and Use of
Laboratory Animals published by the US National Insti-
tutes of Health (NIH Publication No. 85–23, revised 1996)
and the protocol was approved by the Animal Care Com-
mittee of the Italian Ministry of Health (Endorsement
n.135/2008-B). All surgery was performed under anesthesia,
and all efforts were made to minimize suffering.
Animals
Male Wistar rats were either bred in our local animal
husbandry facility or purchased from Harlan Italy s.r.l
(Udine, Italy). Animals were housed in an environment
with controlled 12 h/12 h light/dark cycle, temperature
(21 ± 0.5°C) and relative humidity (55% ± 2%) and fed
with 4 RF 18 standard rat diet for long-term mainten-
ance (Mucedola, Milano, Italy). Water was available ad
libitum.
Cobalt protoporphyrin administration
Cobalt protoporphyrin (CoPP, Frontier Scientific Inc.,
Logan, UT, USA), a well-known inducer of HO-1 ex-
pression [17,18] was administered via intra-peritoneal
injection. We prepared a 5 mg/ml CoPP stock solution
in TRIS buffer (pH 8.0); handling of CoPP solution was
performed in the dark due to its sensitivity to light. The
injected dose was 5 mg/kg body weight.
In order to preliminarily assess the time course of HO-1
protein synthesis after a single injection of CoPP (5 mg/kg),
we monitored cardiac expression of HO-1 protein by
Western blot analysis in 10 control rats sacrificed at dif-
ferent times (0, 8, 16, 24 and 48 h) following CoPP
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Additional file 1: S1). The expression of HO-1 protein
had increased by 16 h and continued to increase
through 48 h (see Additional file 1: Figure S1A). In
addition, to exclude that the rise of HO activity in the
heart forerun the increase in HO-1 abundance (16 h),
we also measured the HO activity in myocardial tissue
(Additional file 1: Figure S1B) at 0 and 8 hours follow-
ing CoPP administration (n = 3 for each time point). No
increase in HO activity was observed at 8 h.
Tin mesoporphyrin administration
Tin mesoporphyrin IX (SnMP, Rockfeller University,
New York, NY, USA), an inducer of HO protein synthe-
sis [20], is considered a potent inhibitor of the activity of
both preformed and newly synthesized enzyme [21,22].
SnMP was administered via intra-peritoneal injection at
a dose of 8 mg/kg body weight.
Induction of myocardial infarction
A total of 144 male Wistar rats 10–12 weeks old and
weighing 310 ± 3 g were used in the study. After thoracot-
omy, MI was induced by ligation of the left anterior de-
scending coronary artery (LAD) (see details in Additional
file 1: S2). Immediately after chest closure rats received an
intra-peritoneal injection of either vehicle alone (TRIS
buffer, MI group, n = 63) or cobalt protoporphyrin alone
(CoPP-treated MI group, n = 40) or CoPP in association
with SnMP (CoPP + SnMP group, n = 8). Due to the > 16
h delay of CoPP induced HO-1 up-regulation, the adopted
scheme of treatment mimicked the clinical condition of a
pharmacological intervention well after initiation of MI.
Thereafter, in order to sustain HO-1 over-expression, add-
itional doses of CoPP or vehicle were administered i.p.
once a week over a 4-week study period. Sham-operated
rats underwent all surgical procedures except LAD
ligation and received the same intra-peritoneal treatment
with vehicle (Sham group, n = 30). In the CoPP + SnMP
group, SnMP was administered i.p. every second day [23].
The number and times of spontaneous deaths during
the 4 weeks were carefully recorded. Out of 144 animals,
three died during surgery due to irreversible ventricular
fibrillation and were not allocated to any group. Thus the
remaining 141 are included in the study. At 4 weeks, a
total of 117 rats survived and entered the morpho-
functional study. Allocation of animals to different groups
and procedures is detailed in the Additional file 1: S3 and
Additional file 1: Table S1.
Electrocardiographic study
ECG was recorded at 2 kHz sampling rate and heart
rate was calculated using the Power Lab monitoring sys-
tem (ML135 PowerLab/8SP) equipped with ML135
Dual Bio Amp and MLA0112 ECG Lead Switch Box(ADI Instruments Ltd., Oxford, UK). ECG recordings were
continuously acquired before (basal condition) and during
surgery up to 60 min. Arrhythmias were classified accord-
ing to the Lambeth Conventions [24] and their severity
was scored (range 0–5) [25] as detailed in the Additional
file 1: S4. Moreover, an extensive ECG analysis was carried
out at 4 weeks after infarction as previously described
[26]. The ECG parameters studied were: heart rate, frontal
QRS axis (ÂQRS) using D1 and AVF leads, and QRS ampli-
tude index (IQRS), i.e., the sum of positive or negative peak
deflections of the QRS complexes in D1, D2 and D3, and
QRS duration (TQRS). ECG at 4 weeks was compared to
the basal one.
Echocardiographic study
Echocardiographic studies were performed 4 weeks after
infarction with a portable ultrasound system (MyLab 25,
Esaote SpA, Genova, Italy) equipped with a high fre-
quency linear transducer (LA523, 12.5 MHz). Under
intra-peritoneal anesthesia, as previously described, im-
ages were obtained from the left parasternal view. A
short-axis 2-dimensional view of the left ventricle (LV)
was taken at the level of papillary muscles to obtain M-
mode recording. Anterior (infarcted) and posterior (viable)
end-diastolic and end-systolic wall thicknesses, systolic
wall thickening, and LV internal dimensions were mea-
sured following the American Society of Echocardiography
guidelines. Parameters were the mean of measurements of
three consecutive cardiac cycles. The global LV systolic
function was expressed as fractional shortening (FS%).
Plasma determination of BNP, ET-1, and PGE2
Plasma samples were assayed to determine the circulating
levels of B-type natriuretic peptide (BNP), endothelin-1
[27,28] and prostaglandin E2 [29], as detailed in the
Additional file 1: S5.
Ex vivo assessment of microvascular reactivity
Microvascular coronary resistance (CR) was evaluated
4 weeks after surgery in the isolated beating heart in
Langendorff configuration. This procedure has been pre-
viously described in detail [30].
Briefly, two side-arms in the perfusion line, located close
to the heart inlet, allowed switching between two reser-
voirs set at normal (70 mmHg) and low (30 mmHg) pres-
sure. Coronary flow was continuously measured with a
flowmeter (model T106, Transonic System Inc, Ithaca,
NY, USA) and by measurement of effluent volume with a
calibrated pipette. Coronary resistance was calculated as
input pressure divided by coronary flow per gram of myo-
cardial tissue (mmHg*g*min/ml). As in infarcted hearts
the injection of Evans blue dye into the aortic root did not
color the infarcted tissue at macroscopic morphometry (in
the Additional file 1: Figure S2), the weight of perfused
Kusmic et al. Journal of Translational Medicine 2014, 12:89 Page 4 of 13
http://www.translational-medicine.com/content/12/1/89myocardium was calculated as the total ventricle weight
minus the necrotic myocardium.
After an initial 15-min period of stabilization, not in-
cluded in the analysis, CR was measured in two alterna-
tive protocols, (i) at the onset and at the end of 65 min
of 70 mmHg perfusion pressure (ii) at 20 min of low
perfusion pressure (30 mmHg) and early after reperfu-
sion at 70 mmHg (peak hyperemia).
Tissue harvesting and macroscopic morphometry
Four weeks after surgery, under deep anesthesia, hearts
were arrested in diastole by a lethal KCl injection, and left
ventricles were weighted and cut in transversal and paral-
lel slices about 2 mm thick. To enhance the contrast be-
tween viable and infarcted myocardium, fresh slices were
incubated with triphenyltetrazolium chloride 1% solution
at 37° for 10 min. Slivers were photographed with a digital
camera and the images processed by dedicated image soft-
ware (MIAO, Myocardial Infarcted Area Outline), which
measured the value of the infarcted area in radiants
encompassing the pale area and expressed it as a percent-
age of the entire left ventricle (360°). The thickness of the
central infarcted area and of its opposite wall were mea-
sured in each animal (see details in Additional file 1: S6).
Next, in each slice, cardiac tissue was divided into four
distinct areas, which were frozen and analyzed separ-
ately: a) right ventricle wall; b) left ventricle posterior
wall, opposite to LAD territory (remote zone); c) border
region to LAD area (border zone); d) central zone of the
infarcted area.
In addition, the abdomen was incised and four samples
from the right and median lobes of the liver were ex-
cised and flash-frozen to determine tissue HO activity.
HO activity measurement in the liver
To define the efficacy of CoPP in inducing HO-1 expres-
sion, HO activity was determined in rat liver micro-
somes of each MI group by measuring bilirubin as
previously described [31]. Details of the procedure are
reported in the Additional file 1: S7.
HO-1 expression
Heart tissue from different cardiac regions was separately
homogenized and blotted on PVDF membrane as detailed
in the Additional file 1: S8. The membranes were probed
with rabbit anti-HO-1. Rabbit anti β-actin or rabbit anti
GAPDH antibodies were used to probe the reference pro-
teins. After incubation with HRP-conjugate secondary
antibody enhanced chemiluminescence detection was per-
formed and digital images were acquired for densitometry
analysis of the bands by using “open source” program
Image J (National Institute of Health, Bethesda MD, USA).
Protein-specific bands were normalized to the protein
loading staining β-actin or GAPDH.Apoptosis
Possible effect of CoPP on cardiac apoptosis was explored
in an especially dedicated additional set of animals (n = 18,
6 sham, 6 untreated MI and 6 CoPP-treated MI rats). Rats
were sacrificed at 16 and 24 h, times proved to correspond
to the onset-time of HO-1 over-expression (n = 3 for each
time in each group). Myocardial tissue homogenates from
infarcted, border and remote regions were processed to
assay caspase 3 activity (Caspase 3 Colorimetric Assay Kit,
AbCam, Cambridge, UK) and to measure BCL-2 levels
(custom made rat BCL-W ELISA kit, RayBiotech, Inc,
Georgia, USA).
Immunohistochemical analysis (connexin 43 and
vascularity)
Hearts were arrested in diastole at 4 weeks, ventricles were
weighted and fixed in 10% buffered formalin (see details in
the Additional file 1: S9). Cardiomyocyte junctions were
identified by immunoperoxidase staining, using a poly-
clonal rabbit anti-connexin 43 (Cx43) primary antibody
(AbCam, Cambridge, UK); arterioles and capillaries were
labeled with anti-smooth muscle actin (α-SMA) primary
antibody (SantaCruz, Dallas, USA) or anti-PECAM 1
(CD31) primary antibody (SantaCruz, Dallas, USA) re-
spectively. Sections were counter-stained with hematoxylin
and examined using light microscopy (Olympus BX43) at
10× to 40× original magnification and digitized by a video
system (Olympus DP20 camera) interfaced to a computer
with dedicated software (CellSens Dimension, Olympus)
for image acquisition and morphometric and/or color ana-
lysis. Cx43 was quantified as the percent of myocardial area
occupied by positive staining (calculated by averaging the
values from ten fields at 10× magnification) for each LV
area. The density (number/mm2) of arterioles (10–100 μm
in diameter) was counted by averaging values from eight
fields randomly chosen for each LV area at 20× magnifica-
tion. The same was done for capillaries density (<10 μm in
diameter), except magnification 40×.
Statistical analysis
All experimental values are expressed as the mean ± stand-
ard error of the mean (SEM). On the basis of the
Kolmogorov-Smirnov test (p > 0.05), the visual inspection
of their histograms, and the normal Q-Q plots we assumed
that our data were approximately normally distributed.
Individual means of different groups were compared
by one-way or two-way analysis of variance (ANOVA)
followed by post hoc Newman-Keuls tests. To take un-
even variances into account, for comparisons between
groups of unequal numbers, Welch’s correction for the
Student’s t-test was used. Correlation analysis was per-
formed using Spearman’s test. Paired or unpaired t-test
and chi-square test were used as appropriate. A value of
p < 0.05 was considered statistically significant.
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Among the 141 animals who survived the surgical pro-
cedure, overall mortality at 4 weeks was 3% in the sham
group, 25% in the vehicle MI group, 12% in the CoPP-
MI group and 25% in the CoPP + SnPP-MI group (in the
Additional file 1: Table S1), with vehicle-MI significantly
different from CoPP-treated MI rats (χ2 = 3.89, p =
0.048) but not different from CoPP + SnMP MI group
(χ2 = 0.167, p = 0.6831). A comparison of vehicle vs CoPP
MI mortality at 24 h (early) and at 72 h (intermediate
mortality) showed that cumulative mortality was similar in
the two groups at 24 h (6 vs 5%) but had diverged at 72 h
(19 vs 7% respectively, χ2 = 6.67, p = 0.0098) supporting
the assumption of a ‘late’ biological effect of our pharma-
cological intervention.
Electrocardiography
In MI groups severe ventricular arrhythmias occurred 5
to 20 min after coronary occlusion. The average severity
score was no different in vehicle when compared to
CoPP and CoPP + SnMP MI groups (3.35 ± 0.15, 3.35 ±
0.11, and 3.33 ± 0.10 respectively) suggesting the absence
of an apparent anti-arrhythmogenic effect of CoPP in
the first 20 min of MI. At 4 weeks, only sporadic ar-
rhythmias were observed, never exceeding a score of 0
in all groups.
QRS morphology, 4 weeks after surgery, showed a dif-
ference between sham and vehicle MI animals with a
rightward shift (> 90°) of the frontal QRS axis, reduction
in QRS amplitude index, and prolongation of QRS inter-
val (Table 1). CoPP treatment significantly decreased the
rightward shift with 53% of cases of ÂQRS axis < 90°, pre-
served QRS amplitude index, partially restored QRS dur-
ation. Concurrent SnMP administration cancelled out
the CoPP effect and abolished ECG morphological dif-
ferences relative to the vehicle MI group.
Echocardiography
The main echocardiographic parameters are shown in
Table 2. LV geometry changed in vehicle MI as the resultTable 1 In vivo heart functional parameters of rats by ECG at
Sham group MI group
n = 20 n = 35
ÂQRS (cases >90°) 59° ± 2 (0/20) 128° ± 2
**# (35/3
IQRS (mV) 4.1 ± 0.2 2.6 ± 0.1
**#
TQRS (ms) 14 ± 0.6 19 ± 0.5
**#
Values are mean ± SEM; n, number of animals tested; ÂQRS, frontal QRS axis; IQRS, QR
#p < 0.001 vs. CoPP-treated infarct.of a progressive LV remodeling over the 4-week study
period post coronary artery ligation. Both LV end-
diastolic and end-systolic diameters, as well as HR in-
creased in untreated MI compared to sham-operated
animals. Moreover, anterior (infarcted) LV wall thickness
was reduced in untreated MI hearts, while the posterior
(viable) wall thickness was higher than sham rats and
CoPP-MI. In vehicle MI the percentage of systolic thick-
ening (an index of contractility) of the anterior and the
posterior walls as well as LV fractional shortening was
reduced compared to sham animals. CoPP treatment
significantly reduced both end-diastolic and end-systolic
diameters of infarcted hearts, blunted both the increase
in heart rate and the thinning of the anterior wall and
improved systolic thickening of both anterior and poster-
ior walls as well as the fractional shortening compared to
untreated MI. Concurrent SnMP administration reversed
the CoPP effect, abolishing both the LV geometry and
functional changes relative to vehicle MI group (Table 2).
Plasma levels of BNP, ET-1 and PGE2
Plasma BNP, ET-1 and PGE2 concentrations before treat-
ment (basal value) were 18 ± 5 pg/mL, 19 ± 0.5 pg/mL,
and 8.1 ± 0.5 ng/mL, respectively. Changes in plasma
concentrations of the three markers 4 weeks after sur-
gery in sham-operated as well as in vehicle- or CoPP-
treated infarcted rats are shown in Additional file 1:
Table S2. Briefly, MI group exhibited an increase in both
BNP (p = 0.06) and ET-1 (p < 0.01) plasma concentra-
tion levels. CoPP treatment dampened the post-infarct
rise of both parameters to levels akin to those of sham-
operated animals. Moreover CoPP caused a significant
increase in PGE2 circulating levels in comparison to
both sham and MI animals.
Effect of CoPP treatment on microvascular coronary
resistance in isolated hearts
Ex vivo measurements of CR are shown in Table 3. Hearts
from sham-operated rats perfused at constant pressure ex-
hibited only a small increase in CR detectable over the 65-
min study period (p < 0.05). In infarcted animals, coronary
resistance values were significantly higher than those in
the sham group (p < 0.001 vs sham-operated). The bolus
administration of papaverine (50 μg), abolished the in-
crease in resistance in infarcted rats, proving its active4 weeks
CoPP-MI group CoPP + SnMP -MI group
n = 25 n = 6
5) 94° ± 5** (12/25) 125° ± 7**# (6/6)
3.6 ± 0.2 2.4 ± 0.2**#
15 ± 0.5 18 ± 1.6**#
S amplitude index; TQRS, QRS duration; **p < 0.001 vs sham-operated;
Table 2 In vivo heart functional parameters of rats by echocardiography at 4 weeks
Heart
function
Sham group MI group CoPP-MI group CoPP + SnMP MI group
n = 20 n = 35 n = 25 n = 6
LVEDd (mm) 5.5 ± 0.2 7.4 ± 0.4**# 6.3 ± 0.3* 8.5 ± 0.4**#
LVESd (mm) 2.0 ± 0.2 5.0 ± 0.3**# 2.9 ± 0.1 6.0 ± 0.4**#
EDAW (mm) 1.6 ± 0.1 1.1 ± 0.1**# 1.5 ± 0.1 1.1 ± 0.1**#
EDPW (mm) 1.6 ± 0.1 1.9 ± 0.1**# 1.6 ± 0.1 1.9 ± 0.7**#
SAWT% 71 ± 3 35 ± 2**# 60 ± 3* 38 ± 5**#
SPWT% 70 ± 2 41 ± 2**# 69 ± 2 52 ± 4**#
FS% 65 ± 3 34 ± 2**# 54 ± 2* 29 ± 3**#
HR 456 ± 7 495 ± 5**# 443 ± 6 470 ± 9#
Values are mean ± SEM; n, number of animals tested; LVEDd, left ventricular end-diastole diameter; LVESd, left ventricular end-systole diameter; EDAW,
end-diastole anterior wall thickness; EDPW, end-diastole posterior (remote) wall thickness; SAWT%, percent systolic anterior wall thickening; SPWT%, percent
systolic posterior (remote) wall thickening; FS%. percent fractional shortening. HR, heart rate. *p < 0.05 and **p < 0.001 vs sham-operated; #p < 0.001 vs
CoPP-treated infarct.
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CoPP treatment blunted the increased coronary resist-
ance observed in infarcted rats (p < 0.01 vs untreated MI)
(Table 3). Treated animals did not differ from sham-
operated ones. In sham-operated hearts, hypotension
caused an increase in coronary resistance (paradoxical
vasoconstriction, p < 0.01 vs baseline). The return to nor-
mal perfusion pressure caused a fall in resistance in the first
minute (hyperemic response) below baseline (p < 0.001 vs
baseline).
As shown in Table 3, in untreated MI hearts,
hypotension induced a marked rise in resistance (p <
0.01 vs sham and CoPP-MI). The return to normal per-
fusion pressure caused a fall in resistance to a value
higher than baseline (p < 0.05 vs baseline). The values of
CR were higher than those of sham-operated animals
(p < 0.001 vs sham-operated rats).
CoPP-treated MI rats showed basal CR values similar
to those of the sham group and lower than those of un-
treated infarct group (p < 0.01 vs untreated infarct). Dur-
ing transient low-pressure ischemia, CoPP treatment inTable 3 Values of coronary resistance in isolated heart in
Langendorff configuration
Sham group MI group CoPP-MI group
Perfusion at constant pressure (70 mmHg)
Baseline 8.8 ± 0.5 13.4 ± 0.5** 9.2 ± 0.5#
65 min 12.5 ± 1.3 32.7 ± 3.3** 17.8 ± 1.8#
Perfusion at low pressure (30 mmHg) and reperfusion
Baseline 9.3 ± 0.6 13.6 ± 0.7** 8.8 ± 0.6#
At 20 min low pressure 15.0 ± 1.6 26.1 ± 2.0* 13.2 ± 1.5#
Reperfusion 8.5 ± 0.5 19.3 ± 0.9** 11.5 ± 0.8
Values are mean ± SEM. *p < 0.01 and **p < 0.001 vs sham-operated;
#p < 0.01 vs MI group.MI rats largely abolished the vasoconstrictive response
to hypotension. At the peak, CR was not significantly
different from that of the sham group. Reperfusion pro-
duced a drop in CR to a level that was no different from
that of the sham-operated group.
Macroscopic morphometry and infarct size
Ventricles of MI group had significantly (p < 0.001) higher
weights than those of sham-operated animals (Additional
file 1: Table S3). CoPP treatment decreased (p < 0.001) the
post-infarct gain in ventricle weight.
Figure 1A shows MI size evaluated 4 weeks after MI
or sham operation. Sham group showed an insignificant
area of LV damage (< 2%), mainly due to tissue trauma
during sham operation. Four weeks after MI, infarct size
was 35.9 ± 1.6% of LV (p < 0.001 vs sham-operated).
Thickness of the core infarcted wall was about 43% of
the one in the sham group, whereas opposite wall thick-
ness was about 119%, a value significantly (p < 0.05)
higher than in sham animals (Additional file 1: Table
S3). CoPP treatment significantly reduced MI size to
23.2 ± 1.3% of LV (p < 0.002 vs untreated MI). Moreover,
it reduced thinning of the core infarcted region (66% of
sham group) and completely prevented the increase in
thickness of the opposite region (101% of sham group).
SnMP resulted in MI size of 33.6 ± 1.5% of LV after
4 weeks (p < 0.001 vs CoPP-MI); thickness of the core
infarcted wall was 39% while the opposite wall was 120%
compared to the sham group.
Liver HO activity
CoPP increased HO activity in the liver of infarcted rats
2.1-fold as compared to untreated infarcted rats (24.0 ±
5.0 vs 11.6 ± 1.5 pmol bilirubin * min-1 * mg-1, p < 0.05).
SnMP-treated animals exhibited minimal HO activity
(0.1 ± 0.08 pmol bilirubin * min-1 * mg-1, p < 0.001 vs
both vehicle and CoPP treated-MI groups).
Figure 1 Histograms of infarct size and HO-1 expression in hearts at 4 weeks after LAD ligation. From left to right: sham operated (n = 6),
vehicle-treated MI (n = 16), CoPP-treated MI (n = 14) and CoPP + SnMP-treated MI rats (n = 6). A. Representative freshly-cut transverse sections used
for determination of infarct size (upper) and quantitative results on infarct size (lower) expressed as mean ± SE percentage of left ventricle. RV:
right ventricle; LVP: left ventricular posterior free wall; LVA: left ventricular anterior free wall. B. Representative western blots (upper) and
quantitative results from densitometric analysis of HO-1 and β-actin expression (lower) of the corresponding regions shown in the areas outlined
by the black boxes and labeled with letters in the representative freshly-cut transverse section: a) right ventricle wall; b) left ventricle posterior
wall, opposite to LAD territory; c) border region to LAD area and d) central zone of the infarcted area. Histograms are expressed as ratio between
HO-1 and the comparative protein β-actin.
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In sham-operated hearts HO-1 protein levels in different
myocardial regions were low (Figure 1B). Conversely, in
the untreated MI group 4 weeks after LAD occlusion,
HO-1 expression levels were significantly increased in
the central zone of the infarcted area. CoPP treatment
resulted in an increase of HO-1 protein levels in all re-
gions compared with both sham and untreated MI
groups (p < 0.001 vs the other groups). Nonetheless in
the CoPP-treated MI group there was a heterogeneous
expression of HO-1 protein in the different myocardial
regions with the highest levels in the core of the in-
farcted area (p < 0.05 vs border zone and p < 0.001 vs
both LV remote zone and RV). Likewise, HO-1 levels in
the border region were about twofold higher than in
both remote area and right ventricle (p < 0.05). Therelative values of HO-1 expression level in each region
of CoPP-treated MI group were: IZ > BZ > RZ = RV.
The addition of SnMP induced a regional pattern and
levels of HO-1 expression in each cardiac region akin to
those of CoPP alone.
Connexin-43
Immunohistochemistry showed a discrete pattern of
connexin-43 staining in LV sections of sham-operated
rats, predominantly localized to the myocyte-myocyte
junction corresponding to intercalated discs. As com-
pared to sham hearts, quantitative analysis of connexin-
43 staining showed a significantly decreased Cx43 in
untreated MI rats both in the remote region (57% ± 8%
of sham, p < 0.001 vs sham group) (Figure 2) and in the
border zone (51% ± 10% of sham, p < 0.001 vs sham
Figure 2 Distribution of connexins 43 in the remote region at 4 weeks after LAD ligation. Upper panels: representative immunostaining
for Cx43 from sham-operated (a), vehicle treated MI (b), CoPP-treated MI (c), and CoPP + SnMP-treated MI groups (d) at low magnification
(10×, calibration bar: 40 μm) and at higher magnification (400×, insets). Lower panel: histograms of the proportion of the total cell area occupied
by Cx43 immunoreactive signal in the remote region. Data are expressed as means ± SE. *p < 0.001 compared with both sham-operated and
CoPP-treated MI groups; #p < 0.02 compared with sham-operated group.
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significant conservation of Cx43 expression in the re-
mote region (84% ± 8% of sham, p < 0.001 vs MI vehicle
group) and also in the border areas (75% ± 16% of sham,
p < 0.02 vs MI vehicle group).
In the SnMP treated group, Cx43 staining was signifi-
cantly lower in both the remote zone (66% of sham, p <0.02 vs sham) and in the border zone (63% of sham, p <
0.05 vs sham), similar to untreated MI hearts.
Arteriolar and capillary density
Figure 3 shows the results of morphometric analysis in
untreated and in CoPP treated animals. In untreated MI,
as compared to the corresponding zones in sham hearts,
Figure 3 Histomorphometric analysis of arteriolar and capillary
density in the border and the remote region at 4 weeks after
LAD ligation. Histograms of arteriolar density (A) and capillary
density (B) in the border (BZ) and the remote (RZ) zone of sham
operated animals (white bar, n = 6), MI group (black bar, n = 6) and
CoPP-treated MI group (dashed bar, n = 6). Data are expressed as
means ± SE. *p < 0.05 and **p < 0.001 compared with sham
operated; #p < 0.05 compared with CoPP-treated MI groups.
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border zone (140%, p = 0.02) as opposite to the capillary
rarefaction in the border (55%, p < 0.001) as well as in
the remote zone (79%, p < 0.05). CoPP treatment further
increased arteriolar density in the border zone (162%,
p < 0.05) and corrected capillary rarefaction partially in
the border zone (69%, p < 0.05 vs untreated MI) while
completely in the remote zone (86% ns).Relationship between measured variables in the
untreated infarcted animals
Correlation matrix of ECG diagnostic signs, anatomical
parameters, indices of LV function, and tissue and
humoral biomarkers (Cx43 and BNP respectively) in
untreated infarcted animals is shown in Additional file 1:
Table S4. Infarct size positively correlated with ÂQRS, indi-
cating that the rightward shift of the frontal axis is a reli-
able index of anterior infarct size in the animal model
used, and with LV enlargement. Remote wall thickness, a
marker of LV remodeling, negatively correlated with LV
function and Cx43 and positively with BNP. Functionalparameters of LV correlated well with ECG diagnostic
signs, with Cx43 staining and BNP.
Effect of HO-1 over-expression on apoptosis early after MI
Hearts untreated and CoPP-treated rats sacrificed at 16
and 24 h after MI were tested for caspase 3 activity and
BCL-W expression level and compared with sham hearts.
(n = 3 for each time in each group). Results did not evi-
dence any significant difference between untreated and
CoPP-treated MI rats either in the caspase 3 activity or in
the level of BCL-W expression. As the BCL-W level is
concerned, a significant increased level of BCL-W at both
16 h (p < 0.05) and 24 h (p < 0.01) was found in the infarct
zone irrespective of treatment with respect to sham oper-
ated animals.
Discussion
The rat model of MI we adopted in the present study
manifested large infarct size but relatively low mortality
(36% of LV and 25% respectively at 4 weeks), thus allow-
ing the study of the long-term efficacy of HO-1 activa-
tion many hours after MI initiation on both mortality
and LV remodeling in survivors. We preferred perman-
ent LAD occlusion to an ischemia-reperfusion model
due to the higher consistence of anatomical and func-
tional findings in this model compared to the much
higher variability proper to the ischemia-reperfusion
one. Moreover, it is a more challenging model for testing
HO-1 efficacy on outcome when a definite ischemic ne-
crosis is already established. The priority of our ‘proof of
concept’ experimental controlled trial was to assess in
evolving myocardial infarction whether late HO-1 over-
expression (i.e., at the time when irreversible ischemic
damage is already established) is still able to improve
outcome (mortality, ventricular dysfunction and left ven-
tricular remodeling). In fact, in absence of such evidence
the previously documented beneficial effect of HO-1
over-expression before MI initiation has no practical
translational meaning due to the clinical inapplicability
of any pharmacological pre-treatment in MI.
In our model, CoPP administration at the end of surgi-
cal procedures was the way of over-expressing HO-1 late
after MI initiation (> 16 h). The beneficial effect of such
treatment on infarct size, cardiac function and ventricular
remodeling implies the ‘late’ occurrence of non-obvious
cellular phenomena that can be addressed by pharmaco-
logical intervention in HO-1 up-regulation and positively
modify final outcome. The mechanisms of such effects
were not the object of the present study and deserve
dedicated investigation. Out of the previously reported
beneficial effect of HO-1 over-expression (anti-oxidative,
anti-inflammatory and anti-apoptotic effects on one hand
and enhanced endothelial function and neoangiogenesis
on the other [10-16]) we could document its positive
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both border and remote zones. Conversely, we were un-
able to document any effect of HO-1 activation on early
(16 and 24 h) cardiac apoptosis. As the time course of
apoptosis following acute MI is still unknown, different re-
sults at different times cannot be ruled out.Untreated infarct
LAD ligation produced a LV antero-lateral transmural
scar, which averaged 35.9 ± 1.6% of the LV 4-weeks after
occlusion, confirming previous data [16,32-34].ECG, LV function and Connexin43
In untreated MI animals the frontal QRS axis (ÂQRS)
shifted to the right, QRS amplitude decreased, while
QRS duration increased when compared to sham ani-
mals. ÂQRS deviation embodies an imbalance in the car-
diac electrical field, due to the loss of an electrically
active area, towards a direction divergent from infarct
location [26,35,36]. In contrast, the decrease in QRS
amplitude reflects the reduction in viable myocardium
that contributes to electrical potential generation as well
as to ventricular function [26]. Finally, the increase in
QRS duration reflects a delay in electrical propagation
through the viable myocardium being generally attributed
to the derangement of the intra-ventricular Purkinje
conduction system and thought to be responsible for
asynchrony of contraction and thus loss of ventricular
systolic function [37]. However, in the interpretation of
ECG changes it should be considered that gap junctions
(clusters of channels constructed from connexins, mainly
Cx43) are a major determinant of the electrical propaga-
tion and electro-mechanical coupling [38,39].
In our study Cx43 staining positively correlated with
QRS amplitude and negatively with QRS duration. Previ-
ous studies have shown decreased QRS amplitude in
genetically restricted Cx43 mice [40,41] and Bacharova
et al. have attributed to Cx43 reduction the discrepancy
between QRS voltage and LV mass in spontaneously
hypertensive rats [42]. Finally, at least two studies have
shown a significant prolongation of QRS complex in het-
erozygous deficient Cx43 mice [38,43].
Regarding myocardial infarction, decreased Cx43 ex-
pression and disorganization of the gap junctions in the
border zone [44] or in the peri-infarct zone [45] or in
both [15,46] have been reported. In contrast, informa-
tion on Cx43 expression and organization in the remote
LV region is very scanty. In line with our findings, de-
creased Cx43 staining in the myocardium far from any
scar has been reported in ischemic patients [47] as well
as in the remote region of infarcted mouse heart [48].
Unfortunately previous studies did not focus on the rela-
tionship of Cx43 with ECG and LV structural andfunctional changes in MI but rather on the putative ar-
rhythmogenic role of Cx43 [46,49,50].
Microvascular reactivity
Compared to sham-operated hearts, untreated infarcted
hearts had a higher basal resistance that progressively in-
creased during prolonged perfusion, and higher vasocon-
strictive response to hypotension. The vasoconstrictive
nature of this increase in resistance was confirmed by its
reversal by papaverine. The finding of increased basal
microvascular resistance is in agreement with the docu-
mented hypo-perfusion of the remote viable region in
patients with chronic myocardial infarction [51,52]. In pre-
vious ex-vivo experiments, we found a similar increase in
coronary resistance in control hearts following L-NAME
[30] suggesting impaired endothelial function and reduced
NO bioavailability in the surviving myocardium. However,
the mechanism(s) underlying the further increase in resist-
ance during hypotension (paradoxical vasoconstriction) in
the remote zone of infarcted heart remains to be eluci-
dated, especially in relation to the observed significant in-
crease of circulating ET-1 in MI as opposed to PGE2.
Effects of post-occlusion CoPP treatment
The preliminary test on the time course of HO-1 over-
expression induced by CoPP i.p. injection in a group of
normal rats indicated that HO-1 over-expression became
apparent 16 h after CoPP administration, and further in-
creased at 24 and at 48 h (Additional file 1: Figure S1).
These results augment previous data from Lakkisto et al.
showing a 1.5-twofold increase in HO-1 protein at 24 h
following a single i.p. injection of CoPP at the same dose
we used, which lasted for 1 week [16]. Continuing in-
crease of HO-1 expression at 48 h confirms a previous
report suggesting a long-lasting effect of CoPP on HO-1
over-expression [17]. In MI animals we administered
CoPP after coronary occlusion, and then once a week
for 4 weeks. This treatment schedule pursued the idea of
inducing HO-1 expression late after LAD occlusion and
sustaining its activation for the 4-week study period. A
powerful and prolonged increase in HO-1 expression
was evident at 4 weeks in all cardiac regions with the
highest level in the infarcted area. Compared to un-
treated MI, CoPP significantly decreased the rate of
spontaneous death beyond 24 h, inferring a beneficial ef-
fect of treatment at delayed times only. Compared to un-
treated MI, CoPP reduced ECG alterations at 4 weeks,
according to the decreased size and transmurality of the
infarct, as well as to the preserved Cx43 architecture in
the remote zone. CoPP treatment improved left ven-
tricular function as assessed in vivo by reduced LV vol-
umes, increased LV fractional shortening and increased
systolic thickening of the viable wall. The above were as-
sociated in vitro with reduced infarct size, no clear
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tion of the Cx43 staining and its spatial organization in
the remote region. SnMP cancelled the beneficial effects
of CoPP, abolishing any differences relative to the un-
treated MI group. This finding focuses on HO activity as
very primarily responsible for the improved conditions
in the heart after LAD occlusion. CoPP also prevented
the increase in heart rate observed in untreated MI. This
finding was likely related to the protective effect of CoPP
on ventricular function and its limitation of heart failure.
The reduction of infarct size by CoPP post-occlusion ad-
ministration is of considerable clinical significance. As
HO-1 up-regulation conceivably began well beyond the
completion of the ischemic necrosis, a process not suscep-
tible to reversibility, one should consider that the infarct
size at 4 weeks in untreated animals was the integrated
result of ischemic plus non-ischemic myocardial loss tak-
ing place late after ischemic necrosis [9]. Moreover, one
should consider additional processes moving in the oppos-
ite direction, i.e., repairing and regenerative processes lim-
iting final infarct size. Lakkisto and colleagues found that
a single injection of CoPP 24 h before LAD ligation was
able to increase cell proliferation and tissue repair and de-
crease the apoptotic loss of cardiomyocytes in the border
area during the first few days after MI [16,53]. This very
dynamic scenario of loss and replacement of myocardial
tissue makes it reasonable to conceive that the increase in
HO activity, although delayed, was able to prevent ‘non-
ischemic’ tissue loss, and/or to exalt regeneration of new
muscular tissue or both.
Although this study does not allow discrimination be-
tween these mechanisms, the higher expression of HO-1
in the infarct area and in the border zone relatively to
the other territories, still evident at 4 weeks after the ini-
tial event, strongly suggests its role in the healing
process of MI. The occurrence of reparative processes
sustained by the formation of new vascular structures
seems to be supported by the finding of increased dens-
ity of both arterioles and capillaries in the present study
following CoPP.
Moreover, CoPP prevented the increase in CR ob-
served ex vivo in the isolated heart of untreated MI
hearts. The effects of CoPP seen here may be partly due
to the end-products of heme degradation, bilirubin and
carbon monoxide, a powerful vasodilator. In addition,
CoPP administration abolished the progressive increase
of resistance during prolonged perfusion, in agreement
with our previous observations obtained in animal
models with critical shortage in both NO production
and bioavailability [54-56].
Conclusion
Previous studies have shown the beneficial effect of HO-1
over-expression in animal models of myocardial infarctionand have widely explored the numerous underlying mo-
lecular mechanisms. However, despite their pathophysio-
logical importance, these studies have no clinical impact
since HO-1 over-expression was induced either by genetic
manipulation or pharmacological pre-treatment, two con-
ditions that are far from the clinical scenario that con-
ceives of treatment only during evolving acute infarction.
In the present study, we provided experimental evidence
that HO-1 over-expression begun late after LAD ligation,
and continuing afterward in the healing and chronic
phase, is still able to reduce mortality, infarct size, left ven-
tricular dysfunction and remodeling. This emphasizes the
dynamic nature of the event ‘infarction’ that cannot be
confined to the post-occlusion myocardial ischemic dam-
age but progresses ahead in a continuum of biological pro-
cesses involving the whole heart.
Our findings support the putative role of pharmaco-
logical induction of HO-1 in the clinical setting, where
medical therapy is always initiated after the onset of in-
farction, in order to obtain benefits in both infarcted and
remote territories, leading to better cardiac function and
auspiciously to better medium- to long-term outcome. In
this perspective, our results support research on novel
pharmacological inducers of HO-1 over-expression in
humans.
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